Recognizing the value of wipe analysis in monitoring the impact of USP <800> compliance efforts, more pharmacy departments are adding this testing to their compounding processes. In a testament to the value wipe analysis delivers, most users are also increasing the frequency of their testing. This expansion should also take into account the variety of sites where contamination may reside beyond the HD cleanroom, from receiving areas and storage spaces to administration areas. Expanding wipe analysis to these sites will provide opportunities to celebrate good practices or improve areas that show contamination.
The utilization of wipe analysis to detect HD residue continues to increase although at a glacial pace. Smaller facilities are less likely to utilize this testing; just 21% of hospitals with fewer than 100 beds have ever conducted wipe analysis, yet that number jumps to 47% for hospitals with 400+ beds.
Most wipe analysis is conducted in the HD compounding room. It is advisable to expand HD wipe testing beyond the cleanroom to monitor practices in HD storage and administration sites.
A growing majority of facilities now conduct wipe analysis on a semiannual basis, which provides clearer trends versus those facilities that only utilize wipe analysis annually.
ChemoGlo and BD continue to enjoy the lion’s share of this marketplace. The Other category includes a number of facilities that either rely on their certifier to conduct testing or use fluoroscein dye and solution testing in lieu of true wipe sampling to monitor staff competency with handling HDs.
Enter our Sweepstakes now for your chance to win the following prizes:
Just answer the following quick question for your chance to win:
Entries are limited to one entry per person in any active sweepstakes.
Thank you for your entry.